




Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > For curative treatment

		<b>EMLc</b>	ATC codes: <b>P01BE02</b>
<b>Indication</b>	Malaria due to Plasmodium vivax	ICD11 code: <b>1F81</b>	
<b>INN</b>	Artemether		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Core (EML) (EMLc)		
<b>Additional notes</b>	For use in the management of severe malaria		
<b>Formulations</b>	Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)		
<b>EML status history</b>	First added in 1997 ( <a href="#">TRS 882</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Wikipedia</b>	<a href="#">Artemether</a> 		
<b>DrugBank</b>	<a href="#">Artemether</a> 		

### Summary of evidence and Expert Committee recommendations

Artemether was added to the core list of the EMLc for the curative treatment of malaria.

